Radiotherapy for solitary plasmacytoma of bone and soft tissue

Outcomes and prognostic factors

Abstract

We investigated treatment outcomes of radiotherapy for solitary plasmacytoma (SP) and prognostic factors affecting survival. Between 1996 and 2010, a total of 38 patients were treated with radiotherapy for histologically proven plasmacytoma without evidence of multiple myeloma. Among these, 16 and 22 patients had SP originating from extramedullary soft tissue (EMP) and bone, respectively. Thirteen patients received adjuvant chemotherapy, and three patients underwent surgery prior to radiotherapy. At a median follow-up of 50 months (range, 8–142), radiotherapy demonstrated excellent local control (5- and 10-year local control rates, 81 %). However, the 10-year multiple myeloma-free survival (MMFS) was 54 % and the 10-year overall survival (OS) rates was 35 %. Solitary bone plasmacytoma (SBP) more frequently progressed to multiple myeloma (MM) than EMP (10-year MMFS, 0 % vs. 71 %, p = 0.02). Radiotherapy with doses ≥40 Gy demonstrated better local control (10-year LC, 100 % vs. 60 %, p = 0.04) in SBP. In the multivariate analysis, elevated β2-microglobulin was a significantly unfavorable prognostic factor affecting OS (p = 0.03). In conclusion, radiotherapy effectively treated SP without significant toxicity. However, progression to MM presents a challenging problem. Novel therapeutics are needed for patients with unfavorable prognostic factors.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Knowling MA, Harwood AR, Bergsagel DE (1983) Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255–262

    PubMed  CAS  Google Scholar 

  2. 2.

    Dimopoulos MA, Hamilos G (2002) Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3:255–259

    PubMed  Article  Google Scholar 

  3. 3.

    Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ (1997) Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer 75:921–927

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Bolek TW, Marcus RB, Mendenhall NP (1996) Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 36:329–333

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengoz M, Scandolaro L, Zouhair A (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210–217

    PubMed  Article  Google Scholar 

  7. 7.

    Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (1998) Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41:1063–1067

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) 16:405–413

    Article  Google Scholar 

  9. 9.

    Kumar S (2008) Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol 83:695–696

    PubMed  Article  Google Scholar 

  10. 10.

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Mayr NA, Wen BC, Hussey DH, Burns CP, Staples JJ, Doornbos JF, Vigliotti AP (1990) The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 17:293–303

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69:1513–1517

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK (2001) Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50:113–120

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin M (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118

    PubMed  Article  Google Scholar 

  15. 15.

    Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R (1992) Curability of solitary bone plasmacytoma. J Clin Oncol 10:587–590

    PubMed  CAS  Google Scholar 

  16. 16.

    Chak LY, Cox RS, Bostwick DG, Hoppe RT (1987) Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol 5:1811–1815

    PubMed  CAS  Google Scholar 

  17. 17.

    Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA (1989) Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16:43–48

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Jawad MU, Scully SP (2009) Skeletal plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2:41

    PubMed  Article  Google Scholar 

  19. 19.

    Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (2002) Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94:1532–1537

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, Katzmann JA (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108:1979–1983

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Duc J, Morel B, Peitrequin R, Frei PC (1988) Identification of monoclonal gammopathies: a comparison of immunofixation, immunoelectrophoresis and measurements of kappa- and lambda-immunoglobulin levels. J Clin Lab Immunol 26:141–146

    PubMed  CAS  Google Scholar 

  22. 22.

    Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, Vazquez L, Garcia-Larana J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, Leon A, Besalduch J, Cabrera R, Miguel JD, Morales A, Garcia-Ruiz JC, Diaz-Mediavilla J, San-Miguel J (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109:438–446

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420

    PubMed  Article  Google Scholar 

  24. 24.

    Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN (1995) Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128–133

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14:111–117

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, Fujiwara M, Shioyama Y, Kagami Y, Shibamoto Y, Nakata K, Takada Y, Kawabe T, Uehara K, Nibu K, Yamada S (2011) Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys 82:626–634

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

All authors have no conflict of interest to declare.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jaeho Cho.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Suh, YG., Suh, CO., Kim, J.S. et al. Radiotherapy for solitary plasmacytoma of bone and soft tissue. Ann Hematol 91, 1785–1793 (2012). https://doi.org/10.1007/s00277-012-1510-6

Download citation

Keywords

  • Plasmacytoma
  • Extramedullary plasmacytoma
  • Solitary bone plasmacytoma
  • Radiotherapy